Dogan Nazile Bilgin, Ozpelit Ebru, Akdeniz Selma, Bilgin Muzaffer, Baris Nezihi
Nazile Bilgin Dogan, MD. Department of Cardiology, Menemen State Hospital, Izmir, Turkey.
Ebru Ozpelit, MD. Department of Cardiology, DokuzEylul University Hospital, Izmir, Turkey.
Pak J Med Sci. 2015;31(3):576-81. doi: 10.12669/pjms.313.7484.
To identify the STEMI patients at high risk in terms of no-reflow during percutaneous coronary intervention (PCI) with a simple risk score system that can be used before reperfusion.
Total 173 patients who had undergone primary or rescue percutaneous coronary intervention following the diagnosis of STEMI, were classified as "no-reflow" developers and "no-reflow" non-developers, during the procedure. The pre-procedural ECGs, laboratory parameters, demographic data, time for the treatment, and the treatment methods were evaluated with univariate analysis. The independent predictors were identified by multivariate logistic regression analysis among the no-reflow risk factors. Using the independent predictors, we developed a simple risk score system proportional to area under the ROC (AUROC) curves.
The independent predictors of "no-reflow" phenomenon were identified as follows: high values of blood glucose at reference; long symptom-onset-to-balloon-time; and low lymphocyte count. The incidence rates of "no-reflow" in patients with low (0-1), moderate (2-3) and high (4-6) risk factors were 13.3%, 40.0%, and 46.7%, respectively. The risk score system demonstrated a good risk prediction between patients with various risk levels of the development of "no-reflow" with a c-statistics of 0.734 (95% CI 0.654-0.814).
The development of "no-reflow" which is an adverse event in STEMI treatment can be predicted efficiently by simple clinical risk scoring method.
用一种可在再灌注前使用的简单风险评分系统,识别经皮冠状动脉介入治疗(PCI)期间发生无复流的高危ST段抬高型心肌梗死(STEMI)患者。
173例诊断为STEMI后接受直接或补救性经皮冠状动脉介入治疗的患者,在手术过程中被分为“无复流”发生者和“无复流”未发生者。对术前心电图、实验室参数、人口统计学数据、治疗时间和治疗方法进行单因素分析。通过多因素逻辑回归分析在无复流危险因素中确定独立预测因素。利用独立预测因素,我们开发了一个与ROC曲线下面积(AUROC)成比例的简单风险评分系统。
“无复流”现象的独立预测因素如下:参考血糖值高;症状发作至球囊扩张时间长;淋巴细胞计数低。低(0 - 1)、中(2 - 3)、高(4 - 6)危险因素患者的“无复流”发生率分别为13.3%、40.0%和46.7%。该风险评分系统在“无复流”发生风险水平不同的患者之间显示出良好的风险预测能力,c统计量为0.734(95%CI 0.654 - 0.814)。
通过简单的临床风险评分方法可以有效预测STEMI治疗中不良事件“无复流”的发生。